CN115667244B - 3-氮杂二环烷基衍生物及包含其的药物组合物 - Google Patents

3-氮杂二环烷基衍生物及包含其的药物组合物 Download PDF

Info

Publication number
CN115667244B
CN115667244B CN202180036112.0A CN202180036112A CN115667244B CN 115667244 B CN115667244 B CN 115667244B CN 202180036112 A CN202180036112 A CN 202180036112A CN 115667244 B CN115667244 B CN 115667244B
Authority
CN
China
Prior art keywords
azabicyclo
methylazetidin
compound
acetic acid
heptan
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202180036112.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN115667244A (zh
Inventor
李成培
尹硕晙
金昌勋
文喜贞
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LG Chem Ltd
Original Assignee
LG Chem Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LG Chem Ltd filed Critical LG Chem Ltd
Publication of CN115667244A publication Critical patent/CN115667244A/zh
Application granted granted Critical
Publication of CN115667244B publication Critical patent/CN115667244B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN202180036112.0A 2020-04-20 2021-04-19 3-氮杂二环烷基衍生物及包含其的药物组合物 Active CN115667244B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20200047190 2020-04-20
KR10-2020-0047190 2020-04-20
PCT/KR2021/004887 WO2021215765A1 (ko) 2020-04-20 2021-04-19 3-아자바이사이클로알킬 유도체 및 이를 포함하는 약제학적 조성물

Publications (2)

Publication Number Publication Date
CN115667244A CN115667244A (zh) 2023-01-31
CN115667244B true CN115667244B (zh) 2024-04-12

Family

ID=78232792

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180036112.0A Active CN115667244B (zh) 2020-04-20 2021-04-19 3-氮杂二环烷基衍生物及包含其的药物组合物

Country Status (7)

Country Link
US (1) US20230203008A1 (cg-RX-API-DMAC7.html)
EP (1) EP4134366A4 (cg-RX-API-DMAC7.html)
JP (1) JP7618338B2 (cg-RX-API-DMAC7.html)
KR (1) KR102614659B1 (cg-RX-API-DMAC7.html)
CN (1) CN115667244B (cg-RX-API-DMAC7.html)
TW (1) TWI810550B (cg-RX-API-DMAC7.html)
WO (1) WO2021215765A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021129737A1 (zh) 2019-12-24 2021-07-01 南京明德新药研发有限公司 具有khk抑制作用的化合物
WO2022022476A1 (zh) * 2020-07-28 2022-02-03 山东轩竹医药科技有限公司 己酮糖激酶抑制剂的盐、晶型及其用途
EP4269404A4 (en) * 2020-12-25 2024-12-04 Xizang Haisco Pharmaceutical Co., Ltd. KETOHEXOKINASE INHIBITORS AND USE THEREOF
JP2024544794A (ja) * 2021-12-24 2024-12-04 エルジー・ケム・リミテッド (s)-2-(2-メチルアゼチジン-1-イル)ピリミジン誘導体およびそれを含む医薬組成物
US20250145619A1 (en) * 2022-02-09 2025-05-08 Youngene Therapeutics Co., Ltd Khk inhibitor, preparation method therefor and use thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107001377A (zh) * 2014-12-08 2017-08-01 爱尔兰詹森科学公司 对呼吸道合胞病毒(rsv)的复制具有抑制活性的哌啶取代的吡唑并[1,5‑a]嘧啶衍生物
CN108473469A (zh) * 2015-12-29 2018-08-31 辉瑞公司 作为己酮糖激酶抑制剂的被取代的3-氮杂双环[3.1.0]己烷
CN113412260A (zh) * 2019-01-29 2021-09-17 山东轩竹医药科技有限公司 己酮糖激酶抑制剂及其用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102558308B1 (ko) * 2018-09-27 2023-07-24 주식회사 엘지화학 3-아자바이사이클로[3,1,1]헵탄 유도체 및 이를 포함하는 약제학적 조성물
EP4269404A4 (en) * 2020-12-25 2024-12-04 Xizang Haisco Pharmaceutical Co., Ltd. KETOHEXOKINASE INHIBITORS AND USE THEREOF

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107001377A (zh) * 2014-12-08 2017-08-01 爱尔兰詹森科学公司 对呼吸道合胞病毒(rsv)的复制具有抑制活性的哌啶取代的吡唑并[1,5‑a]嘧啶衍生物
CN108473469A (zh) * 2015-12-29 2018-08-31 辉瑞公司 作为己酮糖激酶抑制剂的被取代的3-氮杂双环[3.1.0]己烷
CN113412260A (zh) * 2019-01-29 2021-09-17 山东轩竹医药科技有限公司 己酮糖激酶抑制剂及其用途

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Discovery of Fragment-Derived Small Molecules for in Vivo Inhibition of Ketohexokinase (KHK);Kim Huard 等;ACS Medicinal Chemistry Letters;第60卷;第7835−7849页 *
Impact of Physicochemical and Structural Properties on the Pharmacokinetics of a Series of α1L-Adrenoceptor Antagonists;Alison Betts 等;DRUG METABOLISM AND DISPOSITION;第35卷;第1435-1445页 *
Inhibitors of Ketohexokinase: Discovery of Pyrimidinopyrimidines with Specific Substitution that Complements the ATP-Binding Site;Bruce E. Maryanoff 等;ACS Medicinal Chemistry Letters;第2卷;第538–543页 *

Also Published As

Publication number Publication date
EP4134366A1 (en) 2023-02-15
US20230203008A1 (en) 2023-06-29
EP4134366A4 (en) 2023-10-11
KR102614659B1 (ko) 2023-12-19
JP2023522725A (ja) 2023-05-31
JP7618338B2 (ja) 2025-01-21
TW202202492A (zh) 2022-01-16
WO2021215765A1 (ko) 2021-10-28
KR20210129607A (ko) 2021-10-28
CN115667244A (zh) 2023-01-31
TWI810550B (zh) 2023-08-01

Similar Documents

Publication Publication Date Title
AU2020343671B2 (en) RIP1 inhibitory compounds and methods for making and using the same
JP6877407B2 (ja) Ntrk関連障害の治療に有用な化合物および組成物
JP7618338B2 (ja) 3-アザビシクロアルキル誘導体およびこれを含む薬剤学的組成物
JP6494624B2 (ja) カゼインキナーゼ1d/e阻害剤としての置換された4,5,6,7−テトラヒドロピラゾロ[1,5−a]ピラジン誘導体
TWI828712B (zh) 作為trk抑制劑的雜環化合物
CA3114646A1 (en) Quinolino-pyrrolidin-2-one derivatives and application thereof
JP7222590B2 (ja) 3-アザビシクロ[3,1,1]ヘプタン誘導体及びこれを含む薬学的組成物
CN114072407A (zh) 靶向prmt5的化合物
TW200806664A (en) Azaindoles useful as inhibitors of janus kinases
CN115209897A (zh) 雷帕霉素类似物及其用途
EP2961754A1 (de) Benzyl-substituierte pyrazolopyridine und ihre verwendung
WO2022206724A1 (zh) 杂环类衍生物及其制备方法和用途
JP2023522863A (ja) Egfr阻害剤としての三環式化合物
WO2020188467A1 (zh) 作为激酶抑制剂的稠合三环化合物
TW201718583A (zh) 新的表皮生長因子受體抑制劑及其應用
CN117658983A (zh) 选择性parp1抑制剂
EP4186900A1 (en) Codrug that disintegrates in intestine, preparation therefor, and use thereof
EP3197452B1 (en) Inhibitors of hif prolyl hydroxylase
CN120187717A (zh) 1,5-萘啶类cGAS抑制剂及其用途
TW202333697A (zh) Wnt通路抑制劑化合物
CN117384170A (zh) 一种Wnt通路抑制剂化合物
CN116332960A (zh) 一种哒嗪类化合物、其药物组合物及应用
WO2026082051A1 (en) Nitrogen-containing macrocyclic compounds, pharmaceutical composition and use thereof
US20250197411A1 (en) Irak4 protacs
WO2026026969A1 (zh) 作为cGAS抑制剂的化合物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant